Center for Targeted Therapy
Director: Garth Powis, D.Phil.
Planning and fund raising for this center began in 2005. The center's goal is to produce or identify drugs that treat the carcinogenic, genetic and molecular changes that lead to cancer. The Department of Experimental Therapeutics, the building block for the new program, is already working on a number of new chemotherapeutic and biologic agents and novel therapies. The program will grow substantially when the new facility opens.
The Next Frontier: Drugs for Cancer Prevention
The designer drugs produced by this team of 15 scientists will attack defects in cancer cells and in pre-cancerous cells. Molecular and genetic defects in cancer cells can reveal targets specific to each patient, which will be the object of drugs designed to destroy the malignant cells. These targets will also be the next frontier in cancer prevention, allowing physicians to correct or destroy cells with defects before they become a health threat.
A Head Start Advantage
Progress in technologies such as genomics and proteomics and sophisticated bioinformatics analyses has provided the tools and knowledge needed to enhance the design and application of novel cancer therapeutics.
Some of the genetic "abnormalities" found in individual tumors and blood can serve as "cancer markers" that will help researchers identify the genetic profile of each patient's cancer and develop an individualized approach that will be both more effective and less toxic.
Targeted Therapy Articles
How to Help Innovative Research - The institute's interconnected programs offer you a chance to help at an historic moment in the long search for answers to cancer. For more information, you may send a request to email@example.com.
For profiles of faculty and departmental contact information, see Department of Experimental Therapeutics